Ontology highlight
ABSTRACT: Background
Psoriasis is associated with cardiovascular disease and metabolic syndrome but the effects of interleukin (IL)-17A inhibitor treatment on metabolic parameters are unknown. This study aimed to determine the effects of secukinumab on metabolic parameters based on the disease activity and treatment response in patients with psoriasis.Methods
In this retrospective study, we included 99 patients with moderate to severe psoriasis, who received IL-17 inhibitor (secukinumab) treatment for 24 weeks between January 2016 and February 2020. The disease activity [Psoriasis Area and Severity Index (PASI)] and metabolic parameters at baseline and after 12 or 24 weeks of treatment were collected.Results
The PASI improved with a significant reduction of high-sensitivity C
SUBMITTER: Wang HN
PROVIDER: S-EPMC7412909 | biostudies-literature | 2020
REPOSITORIES: biostudies-literature